{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:58Z","timestamp":1792801678124,"version":"4.5.0"},"reference-count":64,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.2967\/jnumed.123.267260","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T17:35:13Z","timestamp":1713461713000},"page":"888-896","source":"Crossref","is-referenced-by-count":24,"title":["A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET\/CT in Genitourinary Cancers"],"prefix":"10.2967","volume":"65","author":[{"given":"Marinus J.","family":"Hagens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurits","family":"Wondergem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry N.","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sanguedolce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela E.","family":"Oprea-Lager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk G.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2024,4,18]]},"reference":[{"key":"2024060510401899000_65.6.888.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"2024060510401899000_65.6.888.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.055"},{"key":"2024060510401899000_65.6.888.3","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.eururo.2023.02.027","article-title":"European Association of Urology-American Society of Clinical Oncology collaborative guideline on penile cancer: 2023 update","volume":"83","author":"Brouwer","year":"2023","journal-title":"Eur Urol."},{"key":"2024060510401899000_65.6.888.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.03.006"},{"key":"2024060510401899000_65.6.888.5","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.eururo.2023.04.010","article-title":"European Association of Urology guidelines on testicular cancer: 2023 update","volume":"84","author":"Patrikidou","year":"2023","journal-title":"Eur Urol."},{"key":"2024060510401899000_65.6.888.6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2023 update","volume":"84","author":"Roupr\u00eat","year":"2023","journal-title":"Eur Urol."},{"key":"2024060510401899000_65.6.888.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30314-7"},{"key":"2024060510401899000_65.6.888.8","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bju.16091","article-title":"Staging fluorodeoxyglucose positron emission tomography\/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study","volume":"132","author":"Richters","year":"2023","journal-title":"BJU Int."},{"key":"2024060510401899000_65.6.888.9","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.euf.2021.02.012","article-title":"F-18 fluorodeoxyglucose positron emission tomography with computed tomography has high diagnostic value for pelvic and distant staging in patients with high-risk penile carcinoma","volume":"8","author":"Ottenhof","year":"2022","journal-title":"Eur Urol Focus."},{"key":"2024060510401899000_65.6.888.10","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.3390\/jcm12103367","article-title":"The implementation of FDG PET\/CT for staging bladder cancer: changes in the detection and characteristics of occult nodal metastases at upfront radical cystectomy?","volume":"12","author":"Einerhand","year":"2023","journal-title":"J Clin Med."},{"key":"2024060510401899000_65.6.888.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08450.x"},{"key":"2024060510401899000_65.6.888.12","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00259-020-04974-w","article-title":"Pelvic lymph-node staging with 18F-DCFPyL PET\/CT prior to extended pelvic lymph-node dissection in primary prostate cancer: the SALT trial","volume":"48","author":"Jansen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401899000_65.6.888.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0007-1"},{"key":"2024060510401899000_65.6.888.14","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1477"},{"key":"2024060510401899000_65.6.888.15","doi-asserted-by":"crossref","first-page":"4946","DOI":"10.3390\/cancers13194946","article-title":"FAP and FAPI-PET\/CT in malignant and non-malignant diseases: a perfect symbiosis?","volume":"13","author":"Dendl","year":"2021","journal-title":"Cancers (Basel)."},{"key":"2024060510401899000_65.6.888.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.01.011"},{"key":"2024060510401899000_65.6.888.17","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/ml300410d","article-title":"Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold","volume":"4","author":"Jansen","year":"2013","journal-title":"ACS Med Chem Lett."},{"key":"2024060510401899000_65.6.888.18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s41181-019-0069-0","article-title":"Targeting of activated fibroblasts for imaging and therapy","volume":"4","author":"Lindner","year":"2019","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2024060510401899000_65.6.888.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.227967"},{"key":"2024060510401899000_65.6.888.20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.215913"},{"key":"2024060510401899000_65.6.888.21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2024060510401899000_65.6.888.22","doi-asserted-by":"publisher","DOI":"10.1177\/0961203316640912"},{"key":"2024060510401899000_65.6.888.23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/RLU.0000000000004719","article-title":"Visualization of intermetastatic heterogeneity in mixed neuroendocrine carcinoma-acinar adenocarcinoma of the prostate by 68Ga-PSMA, 68Ga-FAPI, and 18F-FDG PET\/CT","volume":"48","author":"Cai","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/RLU.0000000000004607","article-title":"68Ga-FAPI-04 PET\/CT in a small sarcomatoid renal cell carcinoma with widespread metastases","volume":"48","author":"Dong","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.25","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11307-022-01715-3","article-title":"Head-to-head intra-individual comparison of [68Ga]-FAPI and [18F]-FDG PET\/CT in patients with bladder cancer","volume":"24","author":"Novruzov","year":"2022","journal-title":"Mol Imaging Biol."},{"key":"2024060510401899000_65.6.888.26","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/RLU.0000000000004349","article-title":"68Ga-FAPI PET\/CT detected non-PSMA\/FDG-avid primary tumor in de novo metastatic prostate cancer","volume":"47","author":"Pang","year":"2022","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/RLU.0000000000003454","article-title":"68Ga-fibroblast activation protein inhibitor, a promising radiopharmaceutical in PET\/CT to detect the primary and metastatic lesions of chromophobe renal cell carcinoma","volume":"46","author":"Pang","year":"2021","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.28","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1097\/RLU.0000000000004550","article-title":"68Ga-FAPI-04 PET\/CT in primary signet ring-like cell carcinoma of prostate with bone metastases","volume":"48","author":"Tatar","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.29","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1097\/RLU.0000000000004522","article-title":"68Ga-PSMA and 68Ga-FAPI-04 PET\/CT findings with 18F-FDG PET\/CT in a patient with recurrent prostate cancer","volume":"48","author":"Tatar","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.30","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1007\/s00259-022-05761-5","article-title":"Feasibility of [68Ga]Ga-FAPI-46 PET\/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma","volume":"49","author":"Unterrainer","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401899000_65.6.888.31","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1007\/s00259-020-05028-x","article-title":"[68Ga]Ga-DOTA-FAPI-04 PET\/CT imaging in a case of prostate cancer with shoulder arthritis","volume":"48","author":"Xu","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401899000_65.6.888.32","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/RLU.0000000000004635","article-title":"Solitary fibrous tumor of the prostate shown on FAPI PET\/CT","volume":"48","author":"Yang","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-021-05488-9","article-title":"FAP imaging in rare cancer entities: first clinical experience in a broad spectrum of malignancies","volume":"49","author":"Dendl","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401899000_65.6.888.34","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/RLU.0000000000004315","article-title":"68Ga-FAPI-46 PET\/CT in a metastatic castration-resistant prostate cancer patient with low PSMA expression","volume":"47","author":"Aryana","year":"2022","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.35","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1097\/RLU.0000000000004587","article-title":"68Ga-FAPI-04 PET\/CT and 18F-FDG PET\/CT in metastatic papillary renal cell cancer","volume":"48","author":"Civan","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.36","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1097\/RLU.0000000000004530","article-title":"68GA-FAPI-04 PET\/CT versus 18F-FDG PET\/CT in imaging of malignant mixed germ cell testicular tumor","volume":"48","author":"Kaplan","year":"2023","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.37","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00259-021-05423-y","article-title":"High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics","volume":"49","author":"Kesch","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401899000_65.6.888.38","doi-asserted-by":"crossref","first-page":"e758","DOI":"10.1097\/RLU.0000000000004374","article-title":"Superiority of 68Ga-FAPI-04 in delineation of soft tissue and liver metastases in chromophobe renal cell carcinoma for restaging","volume":"47","author":"Xie","year":"2022","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.39","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/RLU.0000000000004207","article-title":"68Ga-FAPI-04 PET\/CT in solitary choroid plexus metastasis from renal cell carcinoma","volume":"47","author":"Yang","year":"2022","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s12149-021-01702-8","article-title":"Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging","volume":"36","author":"Kessel","year":"2022","journal-title":"Ann Nucl Med."},{"key":"2024060510401899000_65.6.888.41","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1097\/RLU.0000000000003837","article-title":"Fibroblast activation protein-targeted PET imaging of metastatic castration-resistant prostate cancer compared with 68Ga-PSMA and 18F-FDG PET\/CT","volume":"47","author":"Isik","year":"2022","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.42","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1007\/s00259-019-04623-x","article-title":"Positive FAPI-PET\/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative\/FDG-positive disease","volume":"47","author":"Khreish","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401899000_65.6.888.43","doi-asserted-by":"crossref","unstructured":"Viergever BJ Strating E Lam M . Fibroblast activation protein identifies progressive bladder cancer and allows peritoneal metastasis detection by 68Ga-FAPI PET\/CT imaging. Europe PMC website. https:\/\/europepmc.org\/article\/ppr\/ppr686003. Published July 3, 2023. Accessed March 27, 2024.","DOI":"10.21203\/rs.3.rs-3072623\/v1"},{"key":"2024060510401899000_65.6.888.44","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.euo.2021.01.005","article-title":"Staging 18F-fluorodeoxyglucose positron emission tomography\/computed tomography changes treatment recommendation in invasive bladder cancer","volume":"5","author":"Voskuilen","year":"2022","journal-title":"Eur Urol Oncol."},{"key":"2024060510401899000_65.6.888.45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.euo.2019.09.004","article-title":"Diagnostic value of 18F-fluorodeoxyglucose positron emission tomography with computed tomography for lymph node staging in patients with upper tract urothelial carcinoma","volume":"3","author":"Voskuilen","year":"2020","journal-title":"Eur Urol Oncol."},{"key":"2024060510401899000_65.6.888.46","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1007\/s00259-023-06351-9","article-title":"[18F] AlF-NOTA-FAPI-04 PET\/CT as a promising tool for imaging fibroblast activation protein in gastrointestinal system cancers: a prospective investigation of comparative analysis with 18F-FDG","volume":"50","author":"Yang","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401899000_65.6.888.47","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265712"},{"key":"2024060510401899000_65.6.888.48","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265481"},{"key":"2024060510401899000_65.6.888.49","doi-asserted-by":"crossref","first-page":"e222785","DOI":"10.1148\/radiol.222785","article-title":"FAPI compared with FDG PET\/CT for diagnosis of primary and metastatic lung cancer","volume":"308","author":"Wei","year":"2023","journal-title":"Radiology."},{"key":"2024060510401899000_65.6.888.50","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266329"},{"key":"2024060510401899000_65.6.888.51","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s00259-022-05955-x","article-title":"[18F]FAPI-42 PET\/CT versus [18F]FDG PET\/CT for imaging of recurrent or metastatic gastrointestinal stromal tumors","volume":"50","author":"Wu","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401899000_65.6.888.52","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1007\/s00259-022-05847-0","article-title":"Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management","volume":"49","author":"Qin","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401899000_65.6.888.53","doi-asserted-by":"crossref","first-page":"4377","DOI":"10.1007\/s00259-021-05307-1","article-title":"Head-to-head intra-individual comparison of biodistribution and tumor uptake of 68Ga-FAPI and 18F-FDG PET\/CT in cancer patients","volume":"48","author":"Giesel","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401899000_65.6.888.54","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","article-title":"Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F]FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer","volume":"47","author":"Chen","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401899000_65.6.888.55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00259-020-04940-6","article-title":"Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [18F]FDG PET\/CT findings","volume":"48","author":"Chen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2024060510401899000_65.6.888.56","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.245084"},{"key":"2024060510401899000_65.6.888.57","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/MNM.0000000000001563","article-title":"Physiological tracer distribution and benign lesion incidental uptake of Al18F-NOTA-FAPI-04 on PET\/CT imaging","volume":"43","author":"Kou","year":"2022","journal-title":"Nucl Med Commun."},{"key":"2024060510401899000_65.6.888.58","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1097\/RLU.0000000000003489","article-title":"Fibroblast activation protein inhibitor PET\/CT: a promising molecular imaging tool","volume":"46","author":"Sharma","year":"2021","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.59","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0b013e3283567473"},{"key":"2024060510401899000_65.6.888.60","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/RLU.0000000000003939","article-title":"68Ga-FAPI PET\/CT distinguishes the reactive lymph nodes from tumor metastatic lymph nodes in a patient with nasopharyngeal carcinoma","volume":"47","author":"Shang","year":"2022","journal-title":"Clin Nucl Med."},{"key":"2024060510401899000_65.6.888.61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1358"},{"key":"2024060510401899000_65.6.888.62","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1097\/JU.0000000000003298.03","article-title":"[68Ga]Ga-FAPI-46 PET\/CT prior to surgery in squamous penile cancer: preliminary clinical results [abstract]","volume":"209","author":"Eismann","year":"2023","journal-title":"J Urol."},{"key":"2024060510401899000_65.6.888.63","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2214\/AJR.20.24302","article-title":"Will FAPI PET\/CT replace FDG PET\/CT in the next decade? Point: an important diagnostic, phenotypic, and biomarker role","volume":"216","author":"Calais","year":"2021","journal-title":"AJR."},{"key":"2024060510401899000_65.6.888.64","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259192"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.267260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T17:41:17Z","timestamp":1717609277000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.267260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,18]]},"references-count":64,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,3]]},"published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.2967\/jnumed.123.267260"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.267260","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,18]]}}}